Skip to Main Content

A controversial cost-effectiveness watchdog has declared that Novartis (NVS) priced its recently approved multiple sclerosis drug “far out of line,” the latest slap at the pharmaceutical industry over pricing for such treatments. But critics are using the watchdog’s analysis to push back on the approach it takes to assess the value of new medicines.

In its analysis, the Institute for Clinical and Economic Review determined the $88,500 list price for the Novartis drug, called Mayzent, was not worth the money because the Food and Drug Administration approved the treatment for a different patient population than the one studied in late-stage clinical trials. Because of that, its assessment was modeled on a different group.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!